University of Texas's MD Anderson Cancer Center: Immunotherapy before surgery induces complete response in more than half of patients with common skin cancer in international study
September 12, 2022
September 12, 2022
HOUSTON, Texas, Sept. 12 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Response rates to anti-PD1 monotherapy are the highest reported for any solid tumor
* * *
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or compl . . .
* * *
Response rates to anti-PD1 monotherapy are the highest reported for any solid tumor
* * *
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II-IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or compl . . .